IP Library Granted Patent US 7,019,012
Granted Patent B2
US 7,019,012 · App. 10/023,099 · Granted Mar 28, 2006

Quinazoline derivatives and pharmaceutical compositions containing them

Assignee: Boehringer Ingelheim International Pharma GmbH & Co. KG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,019,012
App. No.
10/023,099
Granted
Mar 28, 2006
Kind
B2
Abstract

A compound of general formula I wherein: R a is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; R b is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and R c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

Claims (24)

1. A compound of formula I

wherein

R a is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group;

R b is a dimethylamino, N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and

R c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,

or a stereoisomer or physiologically acceptable salt thereof.

2. The compound of claim 1 , wherein Rb is a dimethylamino or a stereoisomer or physiologically acceptable salt thereof.

3. The compound of formula I according to claim 1 , wherein:

R a is a 1-phenylethyl or 3-chloro-4-fluorophenyl group;

R b is a dimethylamino, N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N- (tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and

R c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetradrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,

or a stereoisomer or physiologically acceptable salt thereof.

4. The compounds of claim 3 , wherein

R b is a dimethylamino,

or a stereoisomer or physiologically acceptable salt thereof.

5. The compounds of claim 3 , wherein

R a is a 3-chloro-4-fluorohenyl group and

R b is a dimethylamino group,

or a stereoisomer or physiologically acceptable salt thereof.

6. The compound of formula I according to claim 1 , wherein:

R a is a 3-chloro-4-fluorophenyl group;

R b is a dimethylaminno group; and

R c is a tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,

or a steroisomer or physiologically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Oct 6, 2006
From: BOEHRINGER INGELHEIM PHARMA KG
To: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
Reel/Frame 018363/0533 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2002
From: HIMMELSBACH, FRANK; LANGKOPF, ELKE; BLECH, STEFAN; JUNG, BIRGIT; BAUM, ANKE; SOLCA, FLAVIO
To: BOEHRINGER INGELHEIM PHARMA KG
Reel/Frame 012844/0527 →
Priority Claims (1)
DE 100 63 435 · Dec 20, 2000 · national
Continuity (2)
Provisional Application 6025920100 · Dec 18, 2000
Related Publication 20020173509A1 · Nov 21, 2002